1477.HK Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 22:10):

Ocumension Therapeutics, together with its subsidiaries, operates as an ophthalmic pharmaceutical platform company in the People's Republic of China...

Stats
Today's Volume	30 000.00
Average Volume	586 584
Market Cap	4.05B
EPS	HKD0 ( 2023-08-24 )
Last Dividend	HKD0 ( N/A )
Next Dividend	HKD0 ( N/A )
P/E	-9.39
ATR14	HKD0.0150 (0.25%)

Volume Correlation

Long: 0.22 (neutral)

Short: -0.39 (neutral)

Signal:(52.027) Neutral

Ocumension Therapeutics Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Ocumension Therapeutics Correlation - Currency/Commodity

-0.20
( neutral )

0.10
( neutral )

0.00
( neutral )

0.48
( neutral )

0.61
( weak )

0.69
( moderate )

Ocumension Therapeutics Financials

Annual	2023
Revenue:	HKD246.37M
Gross Profit:	HKD144.37M (58.60 %)
EPS:	HKD-0.590

Q2	2023
Revenue:	HKD51.85M
Gross Profit:	HKD31.36M (60.47 %)
EPS:	HKD-0.160

Q1	2023
Revenue:	HKD51.85M
Gross Profit:	HKD31.36M (60.47 %)
EPS:	HKD-0.160

Q4	2022
Revenue:	HKD52.21M
Gross Profit:	HKD34.31M (65.71 %)
EPS:	HKD-0.160

Financial Reports:

No articles found.

Ocumension Therapeutics

Ocumension Therapeutics, together with its subsidiaries, operates as an ophthalmic pharmaceutical platform company in the People's Republic of China. The company discovers, develops, and commercializes therapies for ophthalmic patients. It offers drugs for the treatment of blepharitis, infective and allergic conjunctivitis, dry eye, cataract, glaucoma and ocular hypertension, postoperative inflammation, uveitis, retinitis pigmentosa, age-related macular degeneration, cornea graft rejection, myopia, and optic neuritis. As of December 31, 2021, the company had 20 drug assets in its portfolio. Ocumension Therapeutics was founded in 2017 and is headquartered in Suzhou, the People's Republic of China.